Top Markets
#1 MON MON +2,757.44%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +46.60%
#4 eCash eCash +31.94%
#5 Siren Siren +23.75%
#6 SAFEcoin SAFEcoin +19.98%
#7 Janction Janction +18.96%
#8 PinGo PinGo +15.95%
#9 Velvet Velvet +15.57%
#10 Beldex Beldex +13.32%
Coin of the day
MON MON
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Peringkat dalam Saham #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Harga Saham
$0.30780727
Kapitalisasi Pasar
$94.19M
Perubahan (1 hari)
-0.19%
Perubahan (1 tahun)
-34.73%
Negara
FR
Perdagangan Sensorion SA (ALSEN)

Kategori

Healthcare
Pendapatan untuk Sensorion SA (ALSEN)
Pendapatan pada Dec 2025 TTM: $2.73M
Menurut laporan keuangan terbaru dari Sensorion SA, pendapatan saat ini (TTM) adalah $2.73M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $6.30M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $5.29M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Sensorion SA dari 2011 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $2.73M -60.56%
2024 $6.92M 9.91%
2023 $6.30M 19.02%
2022 $5.29M 9.15%
2021 $4.85M 69.26%
2020 $2.86M 3.92%
2019 $2.76M 7.54%
2018 $2.56M 10.42%
2017 $2.32M 12,505.95%
2016 $18.41K -89.23%
2015 $171.03K -38.96%
2014 $280.18K -42.85%
2013 $490.29K 60.42%
2012 $305.63K 1,124,142.32%
2011 $27.19 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 1,906,201.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 448,772.67%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 546,366.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 332,560.08%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 230,302.17%
NL